Topoisomerase I inhibitors in the treatment of primary CNS malignancies: An update on recent trends

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 9, 2010, Pages 683-696

  Sasine, Joshua P ^a   Savaraj, Niramol ^b   Feun, Lynn G ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Bevacizumab; Glioblastoma; Irinotecan; Malignant glioma; Topoisomerase; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; BEVACIZUMAB; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CELECOXIB; CETUXIMAB; COSITECAN; CYTOCHROME P450; DIFLOMOTECAN; DNA; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EDOTECARIN; EXATECAN; GIMATECAN; IRINOTECAN; LOMUSTINE; LURTOTECAN; RUBITECAN; TEMOZOLOMIDE; THALIDOMIDE; THIOTEPA; TOPOTECAN;

ANAPLASTIC OLIGOASTROCYTOMA; ANAPLASTIC OLIGOSTROCYTOMA; ANEMIA; ANTICONVULSANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CELL MEDIATED CYTOTOXICITY; COLON CARCINOMA; CONTINUOUS INFUSION; CONVULSION; DEEP VEIN THROMBOSIS; DIARRHEA; DNA REPAIR; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; IN VITRO STUDY; INFECTION; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LOADING DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; OXIDATION; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIOSENSITIZATION; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SALVAGE THERAPY; SEIZURE; SKIN TOXICITY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; TUMOR XENOGRAFT; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE;

EID: 79551617962     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794479825     Document Type: Article

References (145)

1. McLendon, R.E.; Halperin, E.C. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer, 2003, 98, 1745-1748.
2. American Cancer Society Cancer Facts and Figures 2009. http://www.Cancer.org (accessed September 10, 2010).
3. Grossman, S.A.; Batara, J.F. Current management of glioblastoma multiforme. Semin. Oncol., 2004, 31, 635-644.
4. CBTRUS Statistical Report: Primary Brain Tumors in the United States, 1998-2002. http://www.cbtrusorg/reports//2005-2006/2006reportpdf2006 (accessed September 10, 2010).
5. Lefranc, F.; Brotchi, J.; Kiss, R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J. Clin. Oncol., 2005, 23, 2411-2422.
6. Brandes, A.A. State-of-the-art treatment of high-grade brain tumors. Semin. Oncol., 2003, 30, 4-9.
7. Reardon, D.A.; Wen, P.Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist, 2006, 11, 152-164.
8. DeAngelis, L.M. Benefits of adjuvant chemotherapy in high-grade gliomas. Semin. Oncol., 2003, 30, 15-18.
9. Cochrane Data. Chemotherapy for high-grade glioma. Cochrane Database Syst Rev., 2002, 4:CD003913.
10. Stewart, L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from twelve randomised trials. Lancet. 2002, 359, 1011-1018.
11. DeAngelis, L. M.; Burger, P.C.; Green, S.B.; Cairncross, J. G. Malignant glioma: who benefits from adjuvant chemotherapy? Ann. Neurol., 1998, 44, 691-695.
12. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352, 987-996.
13. van den Bent, M.J.; Hegi, M.E.; Stupp, R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer, 2006, 42, 582-588.
14. Lefranc, F.; Facchini, V.; Kiss, R. Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas. Oncologist, 2007, 12, 1395-1403.
15. Mathieu, V.; De Neve, N.; Le Mercier, M.; Dewelle, J.; Gaussin, J.F.; Dehoux, M.; Kiss, R.; Lefranc, F. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia, 2008, 10, 1383-1392.
16. Liu, L.; Gerson, S.L. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res., 2006, 12, 328-331.
17. Silber, J.R.; Bobola, M.S.; Ghatan, S.; Blank, A.; Kolstoe, D.D.; Berger, M. S. O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res., 1998, 58, 1068-1073.
18. Donson, A.M.; Addo-Yobo, S.O.; Handler, M.H.; Gore, L.; Foreman, N.K. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr. Blood Cancer., 2007, 48, 403-407.
19. Hegi, M.E.; Diserens, A.C.; Gorlia, T.; Hamou, M.F.; de Tribolet, N.; Weller, M.; Kros, J.M.; Hainfellner, J.A.; Mason, W.; Mariani, L.; Bromberg, J.E.; Hau, P.; Mirimanoff, R.O.; Cairncross, J.G.; Janzer, R.C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med., 2005, 352, 997-1003.
20. Belanich, M.; Pastor, M.; Randall, T.; Guerra, D.; Kibitel, J.; Alas, L.; Li, B.; Citron, M.; Wasserman, P.; White, A.; Eyre, H.; Jaeckle, K.; Schulman, S.; Rector, D.; Prados, M.; Coons, S.; Shapiro, W.; Yarosh, D. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res., 1996, 56, 783-788.
21. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 2000, 343, 1350-1354.
22. Redinbo, M.R.; Stewart, L.; Kuhn, P.; Champoux, J.J.; Hol, W.G. Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA. Science, 1998, 279, 1504-1513.
23. Wang, J.C. DNA Topoisomerases. Annu. Rev. Biochem., 1996, 65, 635-692.
24. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer., 2006, 6, 789-802.
25. Morham, S.G.; Kluckman, K.D.; Voulomanos, N.; Smithies, O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol. Cell. Biol., 1996, 16, 6804-6809.
26. Zhang, H.; Barcelo, J.M.; Lee, B.; Kohlhagen, G.; Zimonjic, D.B.; Popescu, N.C.; Pommier, Y. Human mitochondrial topoisomerase I. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 10608-10613.
27. Zhang, H.; Meng, L.H.; Zimonjic, D.B.; Popescu, N.C.; Pommier, Y. Thirteen-exon-motif signature for vertebrate nuclear and mitochondrial type IB topoisomerases. Nucleic Acids Res., 2004, 32, 2087-2092.
28. Eng, W.K.; Faucette, L.; Johnson, R.K.; Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 1988, 34, 755-760.
29. Nitiss, J.; Wang, J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast.Proc. Natl. Acad. Sci. U. S. A., 1988, 85, 7501-7505.
30. Pommier, Y.; Pourquier, P.; Urasaki, Y.; Wu, J.; Laco, G. S. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat., 1999, 2, 307-318.
31. Wall, M.E.; Wani, M.C. Camptothecin and taxol: discovery to clinic - thirteenth Bruce F. Cain Memorial Award lecture. Cancer Res., 1995, 55, 753-760.
32. Horwitz, S.B.; Horwitz, M.S. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res., 1973, 33, 2834-2836.
33. Hsiang, Y.H.; Lihou, M.G.; Liu, L.F. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 1989, 49, 5077-5082.
34. Holm, C.; Covey, J.M.; Kerrigan, D.; Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res., 1989, 49, 6365-6368.
35. Singh, S.; Dwarakanath, B.S.; Lazar Mathew, T. Role of topoisomerases in cytotoxicity induced by DNA ligand Hoechst-33342 and UV-C in a gliomas cell line. Indian. J. Exp. Biol., 2005, 43, 313-323.
36. Hsiang, Y.H.; Hertzberg, R.; Hecht, S.; Liu, L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 1985, 260, 14873-14878.
37. Friedman, H.S.; Petros, W.P.; Friedman, A.H.; Schaaf, L.J.; Kerby, T.; Lawyer, J.; Parry, M.; Houghton, P.J.; Lovell, S.; Rasheed, K.; Cloughsey, T.; Stewart, E.S.; Colvin, O.M.; Provenzale, J.M.; McLendon, R.E.; Bigner, D.D.; Cokgor, I.; Haglund, M.; Rich, J.; Ashley, D.; Malczyn, J.; Elfring, G.L.; Miller, L.L. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol., 1999, 17, 1516-1525.
38. Slatter, J.G.; Su, P.; Sams, J.P.; Schaaf, L.J.; Wienkers, L.C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos., 1997, 25, 1157-1164.
39. Chen, T.C.; Su, S.; Fry, D.; Liebes, L. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer, 2003, 97, 2363-2373.
40. Weller, M.; Winter, S.; Schmidt, C.; Esser, P.; Fontana, A.; Dichgans, J.; Groscurth, P. Topoisomerase-1 inhibitors for human malignant gliomas: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone. Int. J. Cancer, 1997, 73, 707-714.
41. Takeba, Y.; Sekine, S.; Kumai, T.; Matsumoto, N.; Nakaya, S.; Tsuzuki, Y.; Yanagida, Y.; Nakano, H.; Asakura, T.; Ohtsubo, T.; Kobayashi, S. Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol. Pharm. Bull., 2007, 30, 1400-1406.
42. Innocenti, F. UGT1A1 genotyping in patients undergoing treatment with irinotecan. Clin. Adv. Hematol. Oncol., 2005, 3, 843-844.
43. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 1991, 51, 4187-4191.
44. Coggins, C.A.; Elion, G.B.; Houghton, P.J.; Hare, C.B.; Keir, S.; Colvin, O.M.; Bigner, D.D.; Friedman, H.S. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer Chemother. Pharmacol., 1998, 41, 485-490.
45. Vassal, G.; Terrier-Lacombe, M.J.; Bissery, M.C.; Venuat, A.M.; Gyergyay, F.; Benard, J.; Morizet, J.; Boland, I.; Ardouin, P.; Bressac-de-Paillerets, B.; Gouyette, A. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neu roectodermal tumour and neuroblastoma xenografts. Br. J. Cancer, 1996, 74, 537-545.
46. Blaney, S.M.; Takimoto, C.; Murry, D.J.; Kuttesch, N.; McCully, C.; Cole, D.E.; Godwin, K.; Balis, F.M. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother. Pharmacol., 1998, 41, 464-468.
47. Hare, C.B.; Elion, G.B.; Houghton, P.J.; Houghton, J.A.; Keir, S.; Marcelli, S.L.; Bigner, D.D.; Friedman, H. S. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10- (4- [1-piperidino]-1- piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 1997, 39, 187-191.
48. Fuchs, C.; Mitchell, E.P.; Hoff, P.M. Irinotecan in the treatment of colorectal cancer. Cancer Treat. Rev., 2006, 32, 491-503.
49. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res., 2000, 60, 6921-6926.
50. Innocenti, F.; Undevia, S.D.; Iyer, L.; Chen, P.X.; Das, S.; Kocherginsky, M.; Karrison, T.; Janisch, L.; Ramirez, J.; Rudin, C. M.; Vokes, E. E.; Ratain, M. J. Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol., 2004, 22, 1382-1388.
51. Santos, A.; Zanetta, S.; Cresteil, T.; Deroussent, A.; Pein, F.; Raymond, E.; Vernillet, L.; Risse, M.L.; Boige, V.; Gouyette, A.; Vassal, G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res., 2000, 6, 2012-2020.
52. Kuhn, J.G. Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology, (Williston Park) 2002, 16, 33-40.
53. Crews, K.R.; Stewart, C.F.; Jones-Wallace, D.; Thompson, S.J.; Houghton, P.J.; Heideman, R.L.; Fouladi, M.; Bowers, D.C.; Chintagumpala, M.M.; Gajjar, A. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin. Cancer Res., 2002, 8, 2202-2209.
54. Camptosar [package insert] New York, NY: Pfizer/Pharmacia & Upjohn Co. Licensed from Yakult Honsha Co., Japan, and Daiichi Pharmaceutical Co., Ltd., Japan; 2006.
55. Motl, S.; Zhuang, Y.; Waters, C.M.; Stewart, C.F. Pharmacokinetic considerations in the treatment of CNS tumours. Clin. Pharmacokinet., 2006, 45, 871-903.
56. Macdonald, D.; Cairncross, G.; Stewart, D.; Forsyth, P.; Sawka, C.; Wainman, N.; Eisenhauer, E. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann. Oncol., 1996, 7, 205-207.
57. Friedman, H.S.; Kerby, T.; Fields, S.; Zilisch, J.E.; Graden, D.; McLendon, R.E.; Houghton, P. J.; Arbuck, S.; Cokgor, I.; Friedman, A.H. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke. Cancer, 1999, 85, 1160-1165.
58. Burch, P.A.; Bernath, A.M.; Cascino, T.L.; Scheithauer, B.W.; Novotny, P.; Nair, S.; Buckner, J.C.; Pfeifle, D.M.; Kugler, J.W.; Tschetter, L.K. A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Invest. New Drugs, 2000, 18, 275-280.
59. Lamond, J.P.; Mehta, M.P.; Boothman, D.A. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J. Neurooncol., 1996, 30, 1-6.
60. Blaney, S.M.; Balis, F.M.; Cole, D.E.; Craig, C.; Reid, J.M.; Ames, M.M.; Krailo, M.; Reaman, G.; Hammond, D.; Poplack, D. G. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res., 1993, 53, 1032-1036.
61. Grabenbauer, G.G.; Buchfelder, M.; Schrell, U.; Fahlbusch, R.; Sauer, R.; Staab, H. J. Topotecan as a 21-day continuous infusion with accelerated 3d-conformal radiation therapy for patients with glioblastoma. Front. Radiat. Ther. Oncol., 1999, 33, 364-368.
62. Rich, T.A.; Kirichenko, A.V. Camptothecin radiation sensitization: mechanisms, schedules and timing. Oncology, (Williston Park) 1998, 12, 114-120.
63. Boscia, R.E.; Korbut, T.; Holden, S.A.; Ara, G.; Teicher, B.A. Interaction of topoisomerase I inhibitors with radiation in cisdiamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int. J. Cancer, 1993, 53, 118-123.
64. Kim, J.H.; Kim, S.H.; Kolozsvary, A.; Khil, M. S. Potentiation of radiationresponse in human carcinoma cells in vitro and murine fibrosarcomain vivo by topotecan, an inhibitor or DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys., 1992, 22, 515-518.
65. Lamond, J.P.; Wang, M.; Kinsella, T.J.; Boothman, D. A. Concentration and timing dependence of lethality enhancement between topotecan,a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys., 1996, 36, 361-368.
66. Lamond, J.P.; Wang, M.; Kinsella, T. J.; Boothman, D.A. Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase inhibitors. Int. J. Radiat. Oncol. Biol. Phys., 1996, 36, 369-376.
67. Grabenbauer, G.G.; Anders, K.; Fietkau, R. J.; Klautke, G.; Feldmann, H. J.; Weiser, S.; Staab, H. J.; Krauseneck, P.; Sauer, R. Prolonged infusional topotecan and accelerated hyperfractionated 3dconformal radiation in patients with newly diagnosed glioblastomaa phase I study. J. Neurooncol., 2002, 60, 269-275.
68. Klautke, G.; Schutze, M.; Bombor, I.; Benecke, R.; Piek, J.; Fietkau, R. Concurrent chemoradiotherapy and adjuvant chemotherapy with topotecan for patients with glioblastoma multiforme. J. Neurooncol., 2006, 77, 199-205.
69. Gross, M.W.; Altscher, R.; Brandtner, M.; Haeusser-Mischlich, H.; Chiricuta, I. C.; Siegmann, A.D.; Engenhart-Cabillic, R. Openlabel simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults. Clin. Neurol. Neurosurg., 2005, 107, 207-213.
70. Grabenbauer, G.G.; Gerber, K.D.; Ganslandt, O.; Richter, A.; Klautke, G.; Birkmann, J.; Meyer, M. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys., 2009, 75, 164-169.
71. Lesimple, T.; Riffaud, L.; Frappaz, D.; Ben Hassel, M.; Gedouin, D.; Bay, J. O.; Linassier, C.; Hamlat, A.; Piot, G.; Fabbro, M.; Saikali, S.; Carsin, B.; Guegan, Y. Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study. J. Neurooncol., 2009, 93, 253-260.
72. Fischer, L.; Thiel, E.; Klasen, H.A.; Birkmann, J.; Jahnke, K.; Martus, P.; Korfel, A. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann. Oncol., 2006, 17, 1141-1145.
73. Voloschin, A.D.; Betensky, R.; Wen, P.Y.; Hochberg, F.; Batchelor, T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J. Neurooncol., 2008, 86, 211-215.
74. Wagner, S.; Erdlenbruch, B.; Langler, A.; Gnekow, A.; Kuhl, J.; Albani, M.; Volpel, S.; Bucsky, P.; Emser, A.; Peters, O.; Wolff, J.E. Oral topotecan In children with recurrent or progressive highgrade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. Cancer, 2004, 100, 1750-1757.
75. Bernier-Chastagner, V.; Grill, J.; Doz, F.; Bracard, S.; Gentet, J.C.; Marie-Cardine, A.; Luporsi, E.; Margueritte, G.; Lejars, O.; Laithier, V.; Mechinaud, F.; Millot, F.; Kalifa, C.; Chastagner, P. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer, 2005, 104, 2792-2797.
76. Vrdoljak, E.; Boban, M.; Saratlija-Novakovic, Z.; Jovic, J. Longlasting partial regression of glioblastoma multiforme achieved by edotecarin: case report. Croat. Med. J., 2006, 47, 305-309.
77. Prados, M.D.; Yung, W.K.; Jaeckle, K.A.; Robins, H.I.; Mehta, M.P.; Fine, H.A.; Wen, P.Y.; Cloughesy, T.F.; Chang, S.M.; Nicholas, M.K.; Schiff, D.; Greenberg, H.S.; Junck, L.; Fink, K.L.; Hess, K.R.; Kuhn, J.; North American Brain Tumor Consortium study. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol., 2004, 6, 44-54.
78. Buckner, J.C.; Reid, J.M.; Wright, K.; Kaufmann, S.H.; Erlichman, C.; Ames, M.; Cha, S.; O'Fallon, J.R.; Schaaf, L. J.; Miller, L.L. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer, 2003, 97, 2352-2358.
79. Raymond, E.; Fabbro, M.; Boige, V.; Rixe, O.; Frenay, M.; Vassal, G.; Faivre, S.; Sicard, E.; Germa, C.; Rodier, J.M.; Vernillet, L.; Armand, J. P. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol., 2003, 14, 603-614.
80. Chamberlain, M.C. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J. Neurooncol., 2002, 56, 183-188.
81. Cloughesy, T.F.; Filka, E.; Nelson, G.; Kabbinavar, F.; Friedman, H.; Miller, L.L.; Elfring, G.L. Irinotecan treatment for recurrent malignant glioma using an every-three-week regimen. Am. J. Clin. Oncol., 2002, 25, 204-208.
82. Cloughesy, T.F.; Filka, E.; Kuhn, J.; Nelson, G.; Kabbinavar, F.; Friedman, H.; Miller, L.L.; Elfring, G.L. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an everythree- week regimen. Cancer, 2003, 97, 2381-2386.
83. Batchelor, T.T.; Gilbert, M.R.; Supko, J.G.; Carson, K.A.; Nabors, L.B.; Grossman, S.A.; Lesser, G.J.; Mikkelsen, T.; Phuphanich, S.; NABTT CNS Consortium. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol., 2004, 6, 21-27.
84. Gilbert, M.R.; Supko, J.G.; Batchelor, T.; Lesser, G.; Fisher, J.D.; Piantadosi, S.; Grossman, S. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res., 2003, 9, 2940-2949.
85. Prados, M.D.; Lamborn, K.; Yung, W.K.; Jaeckle, K.; Robins, H.I.; Mehta, M.; Fine, H.A.; Wen, P.Y.; Cloughesy, T.; Chang, S.; Nicholas, M.K.; Schiff, D.; Greenberg, H.; Junck, L.; Fink, K.; Hess, K.; Kuhn, J.; North American Brain Tumor Consortium. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol., 2006, 8, 189-193.
86. Vredenburgh, J.J.; Desjardins, A.; Reardon, D.A.; Friedman, H.S. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol., 2009, 11, 80-91.
87. Wagner, S.; Peters, O.; Fels, C.; Janssen, G.; Liebeskind, A.K.; Sauerbrey, A.; Suttorp, M.; Hau, P.; Wolff, J.E. Pegylatedliposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors. J. Neurooncol., 2008, 86, 175-181.
88. Pipas, J.M.; Meyer, L.P.; Rhodes, C.H.; Cromwell, L.D.; McDonnell, C.E.; Kingman, L.S.; Rigas, J.R.; Fadul, C.E. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J. Neurooncol., 2005, 71, 301-305.
89. Kushner, B.H.; Cheung, N.K.; Kramer, K.; Dunkel, I.J.; Calleja, E.; Boulad, F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant., 2001, 28, 551-556.
90. Gilheeney, S.W.; Khakoo, Y.; Souweidane, M.; Wolden, S.; Boulad, F.; Dunkel, I. J. Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. Pediatr. Blood Cancer, 2010, 54, 591-595.
91. Reardon, D.A.; Quinn, J.A.; Vredenburgh, J.; Rich, J.N.; Gururangan, S.; Badruddoja, M.; Herndon, J.E. 2nd; Dowell, J. M.; Friedman, A.H.; Friedman, H.S. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer, 2005, 103, 329-338.
92. Savaraj, N.; Xu, R.; Wu, C.J.; Landy, H.; Chun, L.; Solomon, J.; Feun, L. Correlation of in vitro antitumor activity of irinotecan and topoisomerase I activity and levels in brain tumor. Proc. Am. Soc. Clin. Oncol., 1995, 14, 482.
93. Feun, L.G.; Marini, A.; Landy, H.; Markoe, A.; Heros, D.; Robles, C.; Herrera, C.; Savaraj, N. Clinical trial of CPT-11 and VM- 26/VP-16 for patients with recurrent malignant brain tumors. J. Neurooncol., 2007, 82, 177-181.
94. Houghton, P.J.; Stewart, C.F.; Cheshire, P.J.; Richmond, L.B.; Kirstein, M.N.; Poquette, C.A.; Tan, M.; Friedman, H. S.; Brent, T.P. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin. Cancer Res., 2000, 6, 4110-4118.
95. Patel, V.J.; Elion, G. B.; Houghton, P.J.; Keir, S.; Pegg, A.E.; Johnson, S.P.; Dolan, M.E.; Bigner, D.D.; Friedman, H.S. Schedule- dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin. Cancer Res., 2000, 6, 4154-4157.
96. Pourquier, P.; Waltman, J.L.; Urasaki, Y.; Loktionova, N.A.; Pegg, A.E.; Nitiss, J.L.; Pommier, Y. Topoisomerase I-mediated cytotoxicity of N-methyl-N-mitro-N-mitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res., 2001, 61, 53-58.
97. Gilbert, M.R.; Wen, P.; Lieberman, F.; Robins, I.; Mehta, M.; Yung, W. K. A.; Chang, S.; Junck, L.; Cloughesy, T.; Prados, M. Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) study [abstract]. Proc. Am. Soc. Clin. Oncol., 2003, 22, 410.
98. Fountzilas, G.; Karkavelas, G.; Kalogera-Fountzila, A.; Karina, M.; Ignatiadis, M.; Koukoulis, G.; Plataniotis, G.; Misailidou, D.; Bobos, M.; Pectasides, D.; Razis, E.; Karavelis, A.; Selviaridis, P. Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res., 2006, 26, 4675-4686.
99. Gruber, M.L.; Buster, W.P. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am. J. Clin. Oncol., 2004, 27, 33-38.
100. Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Desjardins, A.; Vredenburgh, J.; Gururangan, S.; Sathornsumetee, S.; Badruddoja, M.; McLendon, R.; Provenzale, J.; Herndon, J.E.,2nd; Dowell, J.M.; Burkart, J.L.; Newton, H.B.; Friedman, A.H.; Friedman, H.S. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer, 2005, 104, 1478-1486.
101. Quinn, J.A.; Jiang, S.X.; Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; Friedman, A.H.; Sampson, J.H.; McLendon, R.E.; Herndon, J.E. 2nd; Friedman, H.S. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J. Neurooncol., 2009, 95, 393-400.
102. Brandes, A.A.; Tosoni, A.; Basso, U.; Reni, M.; Valduga, F.; Monfardini, S.; Amista, P.; Nicolardi, L.; Sotti, G.; Ermani, M. Secondline chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro- Oncologia (GICNO). J. Clin. Oncol., 2004, 22, 4779-4786.
103. Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Gururangan, S.; Vredenburgh, J.; Sampson, J.H.; Provenzale, J.M.; Walker, A.; Badruddoja, M.; Tourt-Uhlig, S.; Herndon, J.E. 2nd; Dowell, J.M.; Affronti, M.L.; Jackson, S.; Allen, D.; Ziegler, K.; Silverman, S.; Bohlin, C.; Friedman, A.H.; Bigner, D.D.; Friedman, H.S. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol., 2004, 6, 134-144.
104. Quinn, J.A.; Reardon, D.A.; Friedman, A.H.; Rich, J.N.; Sampson, J.H.; Vredenburgh, J.; Gururangan, S.; Provenzale, J.M.; Walker, A.; Schweitzer, H.; Bigner, D.D.; Tourt-Uhlig, S.; Herndon, J.E.,2nd; Affronti, M.L.; Jackson, S.; Allen, D.; Ziegler, K.; Bohlin, C.; Lentz, C.; Friedman, H.S. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol., 2004, 6, 145-153.
105. Rajkumar, S.V.; Witzig, T.E. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat. Rev., 2000, 26, 351-362.
106. Short, S.C.; Traish, D.; Dowe, A.; Hines, F.; Gore, M.; Brada, M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J. Neurooncol., 2001, 51, 41-45.
107. Fine, H.A.; Figg, W.D.; Jaeckle, K.; Wen, P.Y.; Kyritsis, A.P.; Loeffler, J.S.; Levin, V.A.; Black, P.M.; Kaplan, R.; Pluda, J.M.; Yung, W.K. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin. Oncol., 2000, 18, 708-715.
108. Marx, G.M.; Pavlakis, N.; McCowatt, S.; Boyle, F.M.; Levi, J.A.; Bell, D.R.; Cook, R.; Biggs, M.; Little, N.; Wheeler, H.R. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol., 2001, 54, 31-38.
109. Puduvalli, V.K.; Giglio, P.; Groves, M.D.; Hess, K.R.; Gilbert, M.R.; Mahankali, S.; Jackson, E.F.; Levin, V.A.; Conrad, C.A.; Hsu, S.H.; Colman, H.; de Groot, J.F.; Ritterhouse, M.G.; Ictech, S.E.; Yung, W.K. Phase II trial of irinotecan and thalidomide in adult patients with recurrent glioblastoma multiforme. Neuro Oncol., 2008, 10, 216-222.
110. Fadul, C.E.; Kingman, L.S.; Meyer, L.P.; Cole, B.F.; Eskey, C.J.; Rhodes, C.H.; Roberts, D.W.; Newton, H.B.; Pipas, J.M. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J. Neurooncol., 2008, 90, 229-235.
111. Schmidt, N.O.; Westphal, M.; Hagel, C.; Ergun, S.; Stavrou, D.; Rosen, E.M.; Lamszus, K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer, 1999, 84, 10-18.
112. Zhou, Y.H.; Tan, F.; Hess, K.R.; Yung, W.K. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin. Cancer Res., 2003, 9, 3369-3375.
113. Sathornsumetee, S.; Desjardins, A.; Vredenburgh, J.J.; McLendon, R.E.; Marcello, J.; Herndon, J.E.; Mathe, A.; Hamilton, M.; Rich, J.N.; Norfleet, J.A.; Gururangan, S.; Friedman, H.S.; Reardon, D.A. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol., 2010, 12, 1300-1310.
114. Cohen, M.H.; Shen, Y.L.; Keegan, P.; Pazdur, R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist, 2009, 14, 1131-1138.
115. Friedman, H.S.; Prados, M.D.; Wen, P.Y.; Mikkelsen, T.; Schiff, D.; Abrey, L.E.; Yung, W.K.; Paleologos, N.; Nicholas, M.K.; Jensen, R.; Vredenburgh, J.; Huang, J.; Zheng, M.; Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol., 2009, 27, 4733-4740.
116. Olivero, W.C.; Dulebohn, S.C.; Lister, J.R. The use of PET in evaluating patients with primary brain tumors: is it useful? J. Neurol. Neurosurg. Psychiatry, 1995, 58, 250-252.
117. Shields, A.F.; Grierson, J.R.; Dohmen, B.M.; Machulla, H.J.; Stayanoff, J.C.; Lawhorn-Crews, J.M.; Obradovich, J.E.; Muzik, O.; Mangner, T.J. Imaging proliferation in vivo with F-18 FLT and positron emission tomography. Nat. Med., 1998, 4, 1334-1336.
118. Chen, W.; Delaloye, S.; Silverman, D.H.; Geist, C.; Czernin, J.; Sayre, J.; Satyamurthy, N.; Pope, W.; Lai, A.; Phelps, M.E.; Cloughesy, T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol., 2007, 25, 4714-4721.
119. Chen, W.; Cloughesy, T.; Kamdar, N.; Satyamurthy, N.; Bergsneider, M.; Liau, L.; Mischel, P.; Czernin, J.; Phelps, M.E.; Silverman, D. H. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J. Nucl. Med., 2005, 46, 945-952.
120. Chamberlain, M.C.; Johnston, S.K. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J. Neurooncol., 2010, 96, 259-269.
121. Vinjamuri, M.; Adumala, R. R.; Altaha, R.; Hobbs, G.R.; Crowell, E.B., Jr. Comparative analysis of temozolomide (TMZ) versus 1,3- bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients. J. Neurooncol., 2009, 91, 221-225.
122. Zuniga, R.M.; Torcuator, R.; Jain, R.; Anderson, J.; Doyle, T.; Ellika, S.; Schultz, L.; Mikkelsen, T. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J. Neurooncol., 2009, 91, 329-336.
123. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., 2nd; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol., 2007, 25, 4722-4729.
124. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E., 2nd; Dowell, J.M.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Clin. Cancer Res., 2007, 13, 1253-1259.
125. Sathornsumetee, S.; Cao, Y.; Marcello, J. E.; Herndon, J.E., 2nd; McLendon, R.E.; Desjardins, A.; Friedman, H.S.; Dewhirst, M.W.; Vredenburgh, J.J.; Rich, J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol., 2008, 26, 271-278.
126. Hasselbalch, B.; Lassen, U.; Hansen, S.; Holmberg, M.; Sorensen, M.; Kosteljanetz, M.; Broholm, H.; Stockhausen, M.T.; Poulsen, H.S. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol., 2010, 12, 508-516.
127. Xu, T.; Chen, J.; Lu, Y.; Wolff, J.E. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer, 2010, 10, 252.
128. Bokstein, F.; Shpigel, S.; Blumenthal, D.T. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer, 2008, 112, 2267-2273.
129. Desjardins, A.; Reardon, D.A.; Herndon, J.E.,2nd; Marcello, J.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Bailey, L.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S.; Vredenburgh, J.J. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res., 2008, 14, 7068-7073.
130. Goli, K.J.; Desjardins, A.; Herndon, J.E.; Rich, J.N.; Reardon, D.A.; Quinn, J.A.; Sathornsumetee, S.; Bota, D.A.; Friedman, H.S.; Vredenburgh, J.J. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas [abstract]. Proc. Am. Soc. Clin. Oncol., 2007, 25, 2003.
131. Raval, S.N.; Rule, A.; Hwang, S.S. Bevacizumab and Irinotecan In Patients With Recurrent Glioblastoma Multiforme (GBM) [Abstract QL-29] Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO), 2006.
132. Carcaboso, A.M.; Elmeliegy, M.A.; Shen, J.; Juel, S. J.; Zhang, Z.M.; Calabrese, C.; Tracey, L.; Waters, C.M.; Stewart, C.F. Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res., 2010, 70, 4499-4508.
133. Archer, G.; Bigner, D.; Friedman, A.; Friedman, H.; Penne, K.; Lally-Batts, D.; Paolino, A.; Tourt-Uhlig, S.; Reardon, D.; Sampson, J. Dendritic Cell Vaccine for Intracranial Tumors I (DC Victori Trial). Society for Neuro-Oncology, Education Day and Ninth Annual ScientiWc Meeting, Toronto, Ontario, Canada, 2004.
134. Heimberger, A.B.; Hussain, S.F.; Suki, D.; Hess, K.; Shi, W.; Aldape, K.; Crutcher, L.; Gilbert, M.; Sawaya, R.; Archer, G.; Smith, D.; Friedman, H.; Reardon, D.; Friedman, A.; Bigner, D.; Sampson, J.H. (An epidermal Growth Factor Receptor Variant III Peptide Vaccination Appears Promising in Newly Diagnosed GBM Patients: Preliminary Results of a Randomized Phase II Clinical Trial). 74th Annual Meeting of the American Association of Neurological Surgeons, San Francisco, CA, 2006.
135. Kikuchi, T.; Akasaki, Y.; Irie, M.; Homma, S.; Abe, T.; Ohno, T. Results of phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother., 2001, 50, 337-344.
136. Liau, L.M.; Prins, R.M.; Kiertscher, S.M.; Odesa, S.K.; Kremen, T. J.; Giovannone, A.J.; Lin, J.W.; Chute, D.J.; Mischel, P.S.; Cloughesy, T.F.; Roth, M.D. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res., 2005, 11, 5515-5525.
137. Plautz, G.E.; Miller, D.W.; Barnett, G.H.; Stevens, G.H.; Maffett, S.; Kim, J.; Cohen, P. A.; Shu, S. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res., 2000, 6, 2209-2218.
138. Yamanaka, R.; Abe, T.; Yajima, N.; Tsuchiya, N.; Homma, J.; Kobayashi, T.; Narita, M.; Takahashi, M.; Tanaka, R. Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br. J. Cancer, 2003, 89, 1172-1179.
139. Yu, J.S.; Wheeler, C.J.; Zeltzer, P.M.; Ying, H.; Finger, D.N.; Lee, P.K.; Yong, W.H.; Incardona, F.; Thompson, R.C.; Riedinger, M.S.; Zhang, W.; Prins, R.M.; Black, K.L. Vaccination of malignant glioma patients with peptidepulsed dendritic cells elicits sys temic cytotoxicity and intracranial T-cell infltration. Cancer Res., 2001, 61, 842-847.
140. Yu, J.S.; Liu, G.; Ying, H.; Yong, W.H.; Black, K.L.; Wheeler, C.J. Vaccination with tumor lysate-pulsed dendritic cells elicits antigenspeciWc, cytotoxic T-cells in patients with malignant glioma. Cancer Res., 2004, 64, 4973-4979.
141. Wei, J.; DeAngulo, G.; Sun, W.; Hussain, S.F.; Vasquez, H.; Jordan, J.; Weinberg, J.; Wolff, J.; Koshkina, N.; Heimberger, A.B. Topotecan enhances immune clearance of gliomas. Cancer Immunol. Immunother., 2009, 58, 259-270.
142. Du, J.; Lu, W. L.; Ying, X.; Liu, Y.; Du, P.; Tian, W.; Men, Y.; Guo, J.; Zhang, Y.; Li, R. J.; Zhou, J.; Lou, J.N.; Wang, J.C.; Zhang, X.; Zhang, Q. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol. Pharm., 2009, 6, 905-917.
143. Raymond, E.; Campone, M.; Stupp, R.; Menten, J.; Chollet, P.; Lesimple, T.; Fety-Deporte, R.; Lacombe, D.; Paoletti, X.; Fumoleau, P.; EORTC Early Clinical Studies Group (ECSG); Brain Tumor Studies Group (BTSG); New Drug Development Program (NDDP). Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur. J. Cancer, 2002, 38, 1348-1350.
144. Grossman, S.A.; Carson, K.A.; Phuphanich, S.; Batchelor, T.; Peereboom, D.; Nabors, L.B.; Lesser, G.; Hausheer, F.; Supko, J. G.; New Approaches to Brain Tumor Therapy CNS Consortium. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol., 2008, 10, 608-616.
145. Medkoo Biosciences. New anticancer agents under worldwide clinical trials. http://www.medkoo.com/anticancer-trials.htm (Accessed December 27, 2010).